<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB0077</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB0077 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB0077</pre></b></center><p> </p>Introduced 1/9/2025, by Rep. Jackie Haas<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>720 ILCS 570/208</code></td><td class="synopsis"><code>  </code><code>from Ch. 56 1/2, par. 1208</code></td></tr><tr><td class="synopsis"><code>720 ILCS 570/309.1 new</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Amends the Illinois Controlled Substances Act. Schedules xylazine as </code><code>a Schedule III controlled substance. Provides that notwithstanding the </code><code>scheduling of xylazine as a Schedule III controlled substance, xylazine </code><code>shall not be considered a controlled substance when: (1) used by licensed </code><code>Illinois veterinarians dispensing or prescribing for, or administering to, </code><code>a nonhuman species of a drug containing xylazine that has been approved by </code><code>the U.S. Food and Drug Administration; (2) used by licensed Illinois </code><code>veterinarians dispensing or prescribing for, or administering to, a </code><code>nonhuman species that is permissible under the Federal Food, Drug, and </code><code>Cosmetic Act; (3) manufactured, distributed, or used as an active </code><code>pharmaceutical ingredient for manufacturing an animal drug approved under </code><code>the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified </code><code>euthanasia technician employed by a certified euthanasia agency; or (5) </code><code>used by a wildlife biologist engaged in legal or authorized fieldwork </code><code>under the indirect supervision of a veterinarian.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning criminal law.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>The Illinois Controlled Substances Act is </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>amended by changing Section 208 and by by adding Section 309.1 </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>as follows:</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/208)</code><code>  </code><code>(from Ch. 56 1/2, par. 1208)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section before amendment by P.A. 103-881</code><code>)</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 208. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule III.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers (whether optical </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>position, or geometric), and salts of such isomers whenever </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>the existence of such salts, isomers, and salts of isomers is </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>possible within the specific chemical designation;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Those compounds, mixtures, or preparations in </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>dosage unit form containing any stimulant substances </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>listed in Schedule II which compounds, mixtures, or </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>preparations were listed on August 25, 1971, as excepted </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>compounds under Title 21, Code of Federal Regulations, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>Section 308.32, and any other drug of the quantitative </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>composition shown in that list for those drugs or which is </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>the same except that it contains a lesser quantity of </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>controlled substances;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Benzphetamine;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Chlorphentermine;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Clortermine;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Phendimetrazine.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>substances having a potential for abuse associated with a </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>depressant effect on the central nervous system:</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Any compound, mixture, or preparation containing </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>thereof and one or more other active medicinal ingredients </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>which are not listed in any schedule;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Any suppository dosage form containing </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt of </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>any of these drugs and approved by the Federal Food and </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration for marketing only as a suppository;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Any substance which contains any quantity of a </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>derivative of barbituric acid, or any salt thereof:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.1) Aprobarbital;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.2) Butabarbital (secbutabarbital);</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.3) Butalbital;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.4) Butobarbital (butethal); </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Chlorhexadol;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Methyprylon;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Sulfondiethylmethane;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Sulfonethylmethane;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Sulfonmethane;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Lysergic acid;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Lysergic acid amide;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.1) Tiletamine or zolazepam or both, or any salt of </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>either of them.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for a tiletamine-zolazepam
</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>combination product: Telazol.
</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for Tiletamine:
</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for zolazepam:
</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of aspirin;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of acetaminophen;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 50 milligrams of pentazocine or </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>any of its salts plus naloxone HCl USP 0.5 milligrams, per </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>dosage unit;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Ketamine;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Thiopental. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Nalorphine.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d.5) Buprenorphine. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>preparation containing limited quantities of any of the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>following narcotic drugs, or their salts calculated as the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>free anhydrous base or alkaloid, as set forth below:</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>unit, with an equal or greater quantity of an isoquinoline </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>alkaloid of opium;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active non-narcotic ingredients in </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) (blank);</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) (blank);</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) not more than 1.8 grams of dihydrocodeine per 100 </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) not more than 300 milligrams of ethylmorphine per </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>100 milliliters or not more than 15 milligrams per dosage </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) not more than 500 milligrams of opium per 100 </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams, or not more than 25 </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>milligrams per dosage unit, with one or more active, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>amounts;</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) not more than 50 milligrams of morphine per 100 </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams with one or more active, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>amounts.</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Anabolic steroids, except the following anabolic </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>steroids that are exempt:</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Androgyn L.A.;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Andro-Estro 90-4;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) depANDROGYN;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) DEPO-T.E.;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) depTESTROGEN;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Duomone;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) DURATESTRIN;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) DUO-SPAN II;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Estratest;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Estratest H.S.;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) PAN ESTRA TEST;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Premarin with Methyltestosterone;</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) TEST-ESTRO Cypionates;</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Testosterone Cyp 50 Estradiol Cyp 2;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Testosterone Cypionate-Estradiol Cypionate </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>injection; and</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Testosterone Enanthate-Estradiol Valerate </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>injection.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Hallucinogenic substances.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Dronabinol (synthetic) in sesame oil and </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>encapsulated in a soft gelatin capsule in a U.S. Food and </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration approved product. Some other names for </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>(-)-delta-9-(trans)-tetrahydrocannabinol.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (Reserved).</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Department may except by rule any compound, </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>mixture, or preparation containing any stimulant or depressant </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>substance listed in subsection (b) from the application of all </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>or any part of this Act if the compound, mixture, or </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>preparation contains one or more active medicinal ingredients </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>not having a stimulant or depressant effect on the central </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>nervous system, and if the admixtures are included therein in </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>combinations, quantity, proportion, or concentration that </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>vitiate the potential for abuse of the substances which have a </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>stimulant or depressant effect on the central nervous system.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 100-368, eff. 1-1-18</code><code>.)</code><br> </td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(Text of Section after amendment by P.A. 103-881</code><code>)</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 208. </code><code>(a) The controlled substances listed in this </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>Section are included in Schedule III.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>substances having a stimulant effect on the central nervous </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>system, including its salts, isomers (whether optical </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>position, or geometric), and salts of such isomers whenever </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the existence of such salts, isomers, and salts of isomers is </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>possible within the specific chemical designation;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Those compounds, mixtures, or preparations in </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>dosage unit form containing any stimulant substances </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>listed in Schedule II which compounds, mixtures, or </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>preparations were listed on August 25, 1971, as excepted </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>compounds under Title 21, Code of Federal Regulations, </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>Section 308.32, and any other drug of the quantitative </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>composition shown in that list for those drugs or which is </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>the same except that it contains a lesser quantity of </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>controlled substances;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Benzphetamine;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Chlorphentermine;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Clortermine;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Phendimetrazine.</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Unless specifically excepted or unless listed in </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>preparation which contains any quantity of the following </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>substances having a potential for misuse associated with a </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>depressant effect on the central nervous system:</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Any compound, mixture, or preparation containing </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>thereof and one or more other active medicinal ingredients </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>which are not listed in any schedule;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Any suppository dosage form containing </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>amobarbital, secobarbital, pentobarbital or any salt of </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>any of these drugs and approved by the Federal Food and </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration for marketing only as a suppository;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) Any substance which contains any quantity of a </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>derivative of barbituric acid, or any salt thereof:</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.1) Aprobarbital;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.2) Butabarbital (secbutabarbital);</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.3) Butalbital;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3.4) Butobarbital (butethal); </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) Chlorhexadol;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) Methyprylon;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Sulfondiethylmethane;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) Sulfonethylmethane;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) Sulfonmethane;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Lysergic acid;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Lysergic acid amide;</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10.1) Tiletamine or zolazepam or both, or any salt of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>either of them.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for a tiletamine-zolazepam
</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>combination product: Telazol.
</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for Tiletamine:
</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Some trade or other names for zolazepam:
</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of aspirin;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 12.5 milligrams of pentazocine or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>any of its salts, per 325 milligrams of acetaminophen;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) Any material, compound, mixture or preparation </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>containing not more than 50 milligrams of pentazocine or </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>any of its salts plus naloxone HCl USP 0.5 milligrams, per </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>dosage unit;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Ketamine;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Thiopental</code><u><code>;</code></u><code> </code><strike><code>.</code></strike><code> </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(16) dihydro-4H-1,3 thiazin-2-amine), including its </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <u><code>isomers, esters, ethers, salts, and salts of isomers, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <u><code>esters, and ethers, whenever the existence of such </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <u><code>isomers, esters, ethers, and salts is possible within the </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <u><code>specific chemical designation.</code></u><code> </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Nalorphine.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d.5) Buprenorphine. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Unless specifically excepted or unless listed in </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>another schedule, any material, compound, mixture, or </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>preparation containing limited quantities of any of the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>following narcotic drugs, or their salts calculated as the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>free anhydrous base or alkaloid, as set forth below:</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <code>unit, with an equal or greater quantity of an isoquinoline </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>alkaloid of opium;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) not more than 1.8 grams of codeine per 100 </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active non-narcotic ingredients in </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) (blank);</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) (blank);</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) not more than 1.8 grams of dihydrocodeine per 100 </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>milliliters or not more than 90 milligrams per dosage </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) not more than 300 milligrams of ethylmorphine per </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>100 milliliters or not more than 15 milligrams per dosage </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>unit, with one or more active, non-narcotic ingredients in </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>recognized therapeutic amounts;</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) not more than 500 milligrams of opium per 100 </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams, or not more than 25 </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>milligrams per dosage unit, with one or more active, </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>amounts;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) not more than 50 milligrams of morphine per 100 </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>milliliters or per 100 grams with one or more active, </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>non-narcotic ingredients in recognized therapeutic </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>amounts.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Anabolic steroids, except the following anabolic </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>steroids that are exempt:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Androgyn L.A.;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) Andro-Estro 90-4;</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) depANDROGYN;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) DEPO-T.E.;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) depTESTROGEN;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) Duomone;</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(7) DURATESTRIN;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(8) DUO-SPAN II;</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(9) Estratest;</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(10) Estratest H.S.;</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(11) PAN ESTRA TEST;</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(12) Premarin with Methyltestosterone;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(13) TEST-ESTRO Cypionates;</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(14) Testosterone Cyp 50 Estradiol Cyp 2;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(15) Testosterone Cypionate-Estradiol Cypionate </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>injection; and</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(16) Testosterone Enanthate-Estradiol Valerate </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>injection.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) Hallucinogenic substances.</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 12 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) Dronabinol (synthetic) in sesame oil and </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>encapsulated in a soft gelatin capsule in a U.S. Food and </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration approved product. Some other names for </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>(-)-delta-9-(trans)-tetrahydrocannabinol.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) (Reserved).</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Department may except by rule any compound, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>mixture, or preparation containing any stimulant or depressant </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>substance listed in subsection (b) from the application of all </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>or any part of this Act if the compound, mixture, or </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>preparation contains one or more active medicinal ingredients </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>not having a stimulant or depressant effect on the central </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>nervous system, and if the admixtures are included therein in </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>combinations, quantity, proportion, or concentration that </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>vitiate the potential for misuse of the substances which have </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>a stimulant or depressant effect on the central nervous </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>system.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 103-881, eff. 1-1-25.)</code><br> </td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(720 ILCS 570/309.1 new)</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 309.1. </code></u><u><code>Xylazine exemptions. </code></u><u><code>Notwithstanding the </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><u><code>scheduling of xylazine as a Schedule III controlled substance, </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><u><code>xylazine shall not be considered a controlled substance when:</code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(1) used by licensed Illinois veterinarians dispensing or </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><u><code>prescribing for, or administering to, a nonhuman species of a </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB0077</td><td class="xsl" align="center">- 13 -</td><td class="xsl" align="right">LRB104 03201 RLC 13222 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><u><code>drug containing xylazine that has been approved by the U.S. </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><u><code>Food and Drug Administration;</code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(2) used by licensed Illinois veterinarians dispensing or </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><u><code>prescribing for, or administering to, a nonhuman species that </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><u><code>is permissible under the Federal Food, Drug, and Cosmetic Act;</code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(3) manufactured, distributed, or used as an active </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><u><code>pharmaceutical ingredient for manufacturing an animal drug </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><u><code>approved under the Federal Food, Drug, and Cosmetic Act;</code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(4) used by a licensed certified euthanasia technician </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>employed by a certified euthanasia agency; or</code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(5) used by a wildlife biologist engaged in legal or </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>authorized fieldwork under the indirect supervision of a </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>veterinarian.</code></u><br> </td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 95. </code><code>No acceleration or delay. </code><code>Where this Act makes </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>changes in a statute that is represented in this Act by text </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>that is not yet or no longer in effect (for example, a Section </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>represented by multiple versions), the use of that text does </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>not accelerate or delay the taking effect of (i) the changes </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>made by this Act or (ii) provisions derived from any other </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Public Act.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
